Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Nektar Therapeutics
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sun Yat-sen University
University of Arizona
Eli Lilly and Company
Eli Lilly and Company